Improved accessibility to a treatment for kidney disease has been welcomed by Kolling Institute researcher and Royal North Shore Hospital clinician Professor Carol Pollock. Forxiga (dapagliflozin), an oral medicine which can help slow the progression of proteinuric chronic kidney disease, has now been listed on the Pharmaceutical Benefits Scheme. The listing aims to help those with the condition by.....
Read more

Our researchers are seeking participants for a large-scale clinical trial pioneering the use of stem cells to treat and potentially cure osteoarthritis. The disease is now one of the leading causes of disability in the world, affecting around three million people in Australia alone. Royal North Shore Hospital rheumatologist Professor David Hunter is leading the two-year trial which is recruiting ar.....
Read more

New funding will see a large-scale project launched across NSW to significantly improve patient outcomes and experiences in Emergency Departments. Chief investigator and Kolling Institute researcher Professor Margaret Fry said more than $2.8 million will be invested in the EPIC-START program, giving patients better access to early evidence-based treatment pathways. 30 Emergency Departments will ini.....
Read more

Clinicians, researchers and patients have welcomed a landmark law which will pave the way for remarkable new IVF technology to prevent mitochondrial disease. Known as “Maeve’s law” after a young Victorian girl with a rare genetic disorder, the legislation was passed by Federal Parliament allowing the specialised IVF procedure to be carried out in Australia. It will involve replacing faulty mitochon.....
Read more

With large numbers of people across the community looking for effective and lasting ways to treat pain, our researchers at the Kolling Institute are driving nationally significant projects to reduce a reliance on opioid medication and promote proven alternative options. The research by our team from the Pain Management Research Centre follows the latest figures which indicate around 20 per cent of .....
Read more

A team from the Kolling Institute led by Professor Sarah Hilmer has helped develop a valuable, new national program to reduce the adverse impacts of taking multiple medicines. Medicines with an anticholinergic effect can successfully treat many conditions such as depression, dementia and chronic non-cancer pain. Cumulatively however, they can cause serious adverse effects such as falls, confusion, .....
Read more

An important new partnership has been formed to dramatically improve care for musculoskeletal conditions by speeding up the translation of research to clinical practice. The Northern Sydney Local Health District has joined with the University of Sydney and Sydney Local Health District to create Sydney Musculoskeletal Health which will link researchers from across the University with clinicians, con.....
Read more

To mark World Spine Day on October 16, the Back Pain Research team at the Kolling Institute is urging those who experience the condition to adopt the latest advice and keep moving. Spinal pain is extremely common, affecting around 800 million people globally. The condition compromises social, family and work activities, and is the main reason Australians retire involuntarily. The lower back and nec.....
Read more

While the COVID-19 pandemic is interrupting access to some healthcare services, an innovative approach may hold the key to support for those with low back pain. Researchers at the University of Sydney and the Kolling Institute have launched a study to measure the effectiveness of a mobile health program which offers self-management strategies via text messages. Study lead Professor Manuela Ferreira.....
Read more

There are calls for a carefully-considered, tailored approach to the prescription of multiple medicines with new research finding a person’s age and sex influence the impact of multiple medications. More than half of older Australians take five or more regular medications, with the higher number of medications directly linked to a higher chance of adverse reactions, like falls, confusion and frailt.....
Read more